Starting Jan. 1, 2021, patients with inflammatory conditions who are part of the Express Scripts formulary will be forced to switch from the IL-17 inhibitor secukinumab to ixekizumab — whether they or their doctor condone this change or not.The exclusion of secukinumab (Cosentyx, Novartis) in favor of ixekizumab (Taltz, Eli Lilly & Co.) is just one of more than 300 excluded drugs on the Express Script formulary. The 2021 formulary change also excludes an additional 14 specialty drugs for the treatment cardiovascular conditions, type 2 diabetes and pulmonary conditions, and moves 11Read More